US Patent 10,406,172 (SGLT2 + DPP-4 + metformin fixed-dose tablet): claim scope, enforceability, and US competitive patent landscape
Executive summary: US Patent 10,406,172 claims a fixed-dose, single-tablet regimen combining (i) a specific SGLT2 inhibitor (the compound identified in the claims by its chemical name), (ii) linagliptin (or a salt), and (iii) metformin hydrochloride at defined strengths, plus broad downstream method-of-treatment claims covering glycemic control and multiple metabolic indications. The patent’s independent composition claims are narrow in one dimension (exact actives and tablet format) and broad in another (extensive method coverage once the composition is used). Enforceability in the US will most directly hinge on whether accused products are the same chemical SGLT2 species, include linagliptin, include metformin HCl, and are formulated as a single dosage form tablet with the claimed strength combinations (claims 2-5) and/or the claimed strength ranges (claim 1).
What does US Patent 10,406,172 claim, and how broad is the composition scope?
Independent claim 1: fixed-dose, single tablet containing three specific antidiabetics
Claim 1 is an apparatus-style composition claim framed as:
- Single dosage form is a tablet
- Contains, in one dosage form:
- SGLT2 inhibitor identified as:
1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene
with specified amounts: 5, 10, 12.5, or 25 mg
- DPPIV inhibitor is linagliptin (or pharmaceutically acceptable salt)
with specified amounts: 2.5 or 5 mg
- Third antidiabetic agent is metformin hydrochloride
with specified amount: 1000 mg
The claim is not just “triple therapy.” It is a formulation + composition + unit-dose constraint claim.
Scope checkpoints for infringement:
- Must use the exact SGLT2 inhibitor species recited (as a named chemical entity in the claim)
- Must use linagliptin (not another DPP-4 inhibitor)
- Must use metformin hydrochloride
- Must be a single tablet dosage form
- Must fall within one of the SGLT2 strength options and the linagliptin strength options, while metformin is fixed at 1000 mg
Dependent claims 2-5: specific strength embodiments
These claims narrow claim 1 into discrete strength compositions:
| Claim |
SGLT2 inhibitor (mg) |
Linagliptin (mg) |
Metformin HCl (mg) |
Dosage form |
| 2 |
10 |
5 |
1000 |
tablet (single dosage form) |
| 3 |
25 |
5 |
1000 |
tablet |
| 4 |
5 |
2.5 |
1000 |
tablet |
| 5 |
12.5 |
2.5 |
1000 |
tablet |
Interpretive implication: Claim 1 already captures these amounts. Claims 2-5 mainly define clear commercial SKUs that can be mapped to product labels.
Key structural limitation: “single dosage form is a tablet”
This language is a practical enforceability lever. Combination products that are:
- co-packaged but not a single tablet, or
- two tablets/capsules taken together,
may fall outside “single dosage form is a tablet,” depending on claim construction. The claim also does not read on injections, sachets, or multilayer blister dosing unless the claimed “single dosage form” is maintained.
What method-of-use claims does US 10,406,172 cover, and how far do they extend?
Claims 6 through 29 add method claims that are enabled by administering the composition of claim 1 or by administering embodiments of claims 2-5.
Core glycemic control methods (claims 6-13)
- Claims 6-13 cover improving glycemic control for type 2 diabetes mellitus via administering the claimed composition embodiments.
- Administration timing varies by claim:
- Claim 7: “once daily” for the claim 2 embodiment
- Claim 9: “once daily” for the claim 3 embodiment
- Claim 11: “twice daily” for the claim 4 embodiment
- Claim 13: “twice daily” for the claim 5 embodiment
Commercial mapping: once- vs twice-daily can matter for design-around if a product’s dosing regimen is different, though infringement of method claims typically still turns on whether the claimed regimen is practiced.
Broad “slowing progression” and expanded metabolic disorder umbrella (claims 14-21)
Claim 14 expands beyond “glycemic control” to:
- “slowing the progression of, delaying or treating a metabolic disorder selected from the group consisting of”
- T2DM and multiple glucose dysregulation states
- impaired glucose tolerance / impaired fasting blood glucose
- hyperglycemia / postprandial hyperglycemia
- metabolic states like overweight, obesity, metabolic syndrome
- gestational diabetes
- NODAT and complications
- post-transplant metabolic syndrome (PTMS) and complications
Claim 20 further extends to “preventing, slowing the progression of, delaying or treating… complications of diabetes mellitus” including:
- microvascular and macrovascular complications
- nephropathy, retinopathy, neuropathy
- tissue ischemia, diabetic foot
- arteriosclerosis, myocardial infarction, acute coronary syndrome, unstable/stable angina
- stroke, peripheral arterial occlusive disease
- cardiomyopathy, heart failure, heart rhythm disorders
- vascular restenosis
Scope note: the method claims are still tied to the actives via the “characterized in that” language requiring administration of an SGLT2 inhibitor + linagliptin + metformin according to claim 1.
Weight/fat and ectopic fat-related methods (claims 22-27)
- Claims 22-23 target reducing body weight and/or fat (or preventing increases).
- Claims 26-27 target diseases/conditions attributed to abnormal accumulation of ectopic fat.
Hyperuricemia / kidney stones / hyponatremia methods (claims 28-29)
Claim 28 covers:
- preventing/treating hyperuricemia
- hyperuricemia-associated conditions
- kidney stones
- hyponatremia
Pancreatic beta-cell functionality methods (claims 24-25)
Claim 24 covers degeneration of beta cells, decline in functionality, restoring beta-cell functionality, and insulin secretion restoration.
Method claims are broad in indication space but narrow in “composition used.” They will be hard to avoid if an accused product matches claim 1 composition and is used for a claimed indication.
How do the “patient condition” subclauses (claims 15, 17, 19, 21, 23, 25, 27, 29) limit practice?
Several method claims include detailed patient qualification language, such as:
- diagnosed overweight/obesity/visceral/abdominal obesity, or
- lab thresholds:
- fasting or serum glucose >110 mg/dL (notably >125 mg/dL)
- postprandial plasma glucose ≥140 mg/dL
- HbA1c ≥6.5% (notably ≥7.0%)
- metabolic criteria:
- triglycerides ≥150 mg/dL
- HDL <40 mg/dL in females and <50 mg/dL in males
- blood pressure ≥130/85 mm Hg
- fasting glucose ≥100 mg/dL
- insufficient glycemic control despite diet/exercise or monotherapy or combination therapy
Practical consequence: If an accused product is used in patients who do not meet these subclauses, the specific dependent method claim may not be practiced. Independent method claims without those subclauses may still be asserted.
Which SGLT2 inhibitor is recited, and what does that mean for infringement risk?
The SGLT2 inhibitor in claim 1 is defined by its chemical structure name. For risk mapping, this is decisive:
- If the accused product uses that exact SGLT2 molecular entity, the SGLT2 limitation is met.
- If it uses a different SGLT2 inhibitor (e.g., dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, or others), it may fall outside the literal scope.
Because claim 1 uses the chemical name rather than a class phrase like “any SGLT2 inhibitor,” the literal scope is tied to that single species.
Enforcement leverage: this is a high-friction literal constraint for generics unless they are copying the same SGLT2 active.
What patent landscape surrounds US 10,406,172: where are the gaps and where overlap is likely?
1) Composition patent layer vs. method layer
US 10,406,172 is a composition + method hybrid:
- Composition claims (1-5) depend on fixed-dose tablet structure and actives.
- Method claims (6-29) attach broad clinical endpoints to administration of the composition.
In most combination-drug ecosystems, the landscape often separates into:
- core drug substance patents for the individual actives (SGLT2, linagliptin, metformin compositions),
- combination formulation patents,
- and method patents for specific multi-drug regimens or use populations.
Implication for freedom-to-operate (FTO): even if a competitor designs around the exact triple fixed-dose composition, they still face method-use exposure if the specific combination is practiced under a claimed indication in a covered dosing regimen (where dependent timing claims exist).
2) Strength-locked fixed-dose embodiments
Claims 2-5 define specific tablet strengths. Generic or branded competitors often commercialize a finite set of strengths. If a product is close but differs (for example, different linagliptin mg strength or different SGLT2 mg strength), it may avoid some dependent claims but could still fall within claim 1 depending on strength coverage.
3) Tablet-only limitation as an IP design barrier
If a competitor launches a regimen as:
- separate tablets (SGLT2 + linagliptin + metformin taken together),
- or a different solid form,
the “single dosage form is a tablet” element is an avoidable trigger if properly designed.
4) DPP-4 limitation to linagliptin
The DPPIV inhibitor must be linagliptin. Substitution with another DPP-4 inhibitor is an obvious design-around if commercially feasible.
What generic entry risks exist for competitors under US 10,406,172?
Scenario A: Generic triple fixed-dose tablet (literal copy)
Highest risk:
- same SGLT2 species recited,
- linagliptin,
- metformin HCl 1000 mg,
- and tablet unit-dose matched to claimed strengths.
If the generic company markets and instructs use in claimed indications and dosing schedules, method claims are also in play.
Scenario B: Similar triple therapy with different SGLT2
Lower risk:
- if SGLT2 active is not the claimed chemical entity, composition claim 1 likely fails at the first actives element.
Scenario C: Similar triple therapy with a different DPP-4 inhibitor
Lower risk:
- claim requires linagliptin.
Scenario D: Similar actives but non-tablet dosage form
Lower risk:
- claim requires “single dosage form is a tablet.”
Scenario E: Similar actives in co-pack regimen
Lower risk on composition:
- claim requires a single tablet dosage form, not merely combined administration.
How strong is the patent estate for this triple regimen? (Claim-level strength, not portfolio-wide)
On a claim-by-claim basis, strength indicators are:
Strong points
- The chemical definition of the SGLT2 inhibitor is specific.
- Linagliptin is fixed.
- Metformin HCl is fixed at 1000 mg.
- The dosage form is fixed to tablet.
Weak points
- The method claims are broad in indications (many complications and metabolic disorders). Broad indication coverage can increase vulnerability depending on legal standards for written description, enablement, and whether the claimed outcomes are supported by the patent’s disclosure. (Assessment of that validity risk depends on the patent specification, which is not provided here.)
How do you use US 10,406,172 in litigation or licensing: key claim targets
Composition infringement targets (fastest path)
- Assert claim 1 first: it is the broadest composition claim and is common to all dependent composition embodiments.
- Then assert claims 2-5 for direct strength mapping to product labels.
Method claim targets (when prescription information exists)
- Use dependent method claims only where patient selection criteria and dosing frequency match the product’s label and marketed regimen.
- For broader indications, deploy independent method claim 14/16/18/20/22/24/26/28 where available, because these cover wider indications even if specific subclauses are not satisfied.
Key Takeaways
- US 10,406,172 is centered on a single-tablet fixed-dose combination of an explicitly defined SGLT2 inhibitor, linagliptin, and metformin hydrochloride 1000 mg.
- Claims 2-5 lock to specific commercial strength combinations and are directly mappable to tablet SKUs.
- Method-of-use claims (6-29) are wide-ranging in indication scope, but still require administration of the patented triple combination; multiple dependent claims add patient qualification and dosing-frequency constraints.
- The most meaningful design-arounds are:
- changing the SGLT2 chemical entity,
- changing linagliptin to another DPP-4 inhibitor,
- changing from a single tablet dosage form to separate/co-pack regimens,
- or changing the strength combinations outside claim 1’s covered options (with dependent claims 2-5 serving as extra anchors).
FAQs
-
Does US 10,406,172 cover combination use taken as separate tablets (co-pack)?
The claims require a “single dosage form is a tablet,” so separate dosage forms are outside the asserted composition structure.
-
Can a product with a different DPP-4 inhibitor avoid claim 1?
Yes, because claim 1 requires the DPPIV inhibitor to be linagliptin (or salt).
-
Are the method claims dependent on once-daily vs twice-daily dosing?
Some dependent claims specify once-daily (claims 7, 9) or twice-daily (claims 11, 13). Those timing elements matter for those specific dependent method claims.
-
If the SGLT2 active is not the exact chemical entity named, does claim 1 still apply?
Claim 1 identifies a specific SGLT2 inhibitor chemical entity, so using a different SGLT2 active should avoid literal scope.
-
Which claims are most important for a generic or biosimilar competitor assessing launch risk?
The composition claims 1 and 2-5 are the primary infringement anchors; method claims become relevant when product labels and prescribing practices match claimed indications and regimens.
References (APA)
(No sources cited. The prompt provides claim text only and does not supply publication metadata, prosecution history, Orange Book listings, FDA application numbers, or the patent specification.)
